Skip links

OncOne’s CSO Michael Thiele published a new review article on oxMIF

Our CSO, Michael Thiele has published the review article “OxMIF: a druggable isoform of macrophage migration inhibitory factor in cancer and inflammatory diseases” in the Journal for Immunotherapy of Cancer. With support from OncoOne’s new SAB members, Dr. Seamas Donnelly and Dr. Robert Mitchell, Michael highlights the potential of oxMIF as an attractive therapeutic target capable of overcoming the challenges posed by the Macrophage Migration Inhibitory Factor (MIF).

Home